摘要
目的观察分析地特胰岛素与瑞格列奈共同治疗2型糖尿病的效果与安全性。方法将2017年6月—2018年4月入该院接受治疗的100例2型糖尿病患者采用随机分组法分为对照组与观察组,两组患者均为50例,予以对照组患者诺和灵30R进行治疗,观察组患者实施地特胰岛素与瑞格列奈共同治疗,观察比较两组患者经相应治疗后血糖指标情况,以及不良反应发生率。结果数据显示两组患者血糖与治疗前相比均得到明显下降,观察组患者血糖各项指标改善情况均优于对照组患者,同时,观察组患者不良反应发生率明显低于对照组患者,组间各项数据比较差异有统计学意义(P<0.05)。结论在2型糖尿病患者的治疗中,地特胰岛素和瑞格列奈联合应用可有效降低血糖水平和糖化血红蛋白,降低血糖波动,减少低血糖发生情况,进一步提高药物安全性,值得临床应用。
Objective To observe the efficacy and safety of insulin detemir and repaglinide in the treatment of type 2 diabetes.Methods 100 patients with type 2 diabetes who were admitted to our hospital from June 2017 to April 2018 were randomly divided into the control group and the observation group.The two groups were 50 patients each,and the control group was treated with Novo 30 R.The patients in the observation group were treated with detemir and repaglinide.The blood glucose levels and the incidence of adverse reactions were compared between the two groups.Results It showed that the blood glucose of both groups was significantly lower than that before treatment.The improvement of blood glucose index in the observation group was better than that of the control group.At the same time,the incidence of adverse reactions in the observation group was significantly lower than that in the control group.The data were significantly different,and the statistical significance was significant(P<0.05).Conclusion In the treatment of type 2 diabetes,the combination of insulin detemir and repaglinide can effectively lower blood glucose levels and glycosylated hemoglobin,and reduce blood glucose fluctuations.To reduce the incidence of hypoglycemia and further improve the safety of drugs,it is worthy of clinical application.
作者
管辉
GUAN Hui(Jiangzhuang Town Health Center,Gaomi,Shandong Province,261506 China)
出处
《糖尿病新世界》
2019年第11期73-74,共2页
Diabetes New World Magazine
作者简介
管辉(1972-),女,山东高密人,本科,主治医师,研究方向:临床内科专业。
